\

Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Turning the Tide on Cancer

Investing in Cardiff Oncology to Provide New Treatment Options for Cancers with the Greatest Medical Need

Press Releases

Get News Alerts by Email

Mar 3, 2021

Cardiff Oncology to Present at H.C. Wainwright Global Life Sciences Conference
Feb 25, 2021

Cardiff Oncology Announces Fourth Quarter and Full Year 2020 Results and Recent Highlights
Feb 24, 2021

Cardiff Oncology to Participate in Gastrointestinal (GI) Oncology and Pancreatic Cancer Panel Discussion at the Cowen 41st Annual Health Care Conference
Feb 16, 2021

Cardiff Oncology to Present at the LifeSci Partners Precision Oncology Day
Feb 11, 2021

Cardiff Oncology Presents Phase 2 mCRPC Trial Data Showing a Two-Fold Increase in Efficacy with an Optimized Onvansertib Dosing Schedule

- Two-fold increase (29% to 63%) in disease control rate at 12 weeks (the trial's primary efficacy endpoint) seen in patients receiving onvansertib for 14 days vs. 5 days in a 21-day cycle

Show per page